Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aleglitazar in Type 2 Diabetes and Chronic Kidney Disease (ALERENAL)
NCT01893242Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Dec 2013
- Primary completion
- Jan 2019
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of aleglitazar in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by Roche. Planned start Dec 2013; status: withdrawn.
02
Drugs
aleglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT01893242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01893242.